Loading…
Ovid Therapeutics Inc. is projected to rise to $3.67 by 2027, a +44% move from its current price of $2.54. OVID is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.46 | $2.54 | $2.62 | +0.05% |
| May 30 | $2.43 | $2.54 | $2.66 | +0.11% |
| May 31 | $2.41 | $2.54 | $2.69 | +0.16% |
| Jun 1 | $2.39 | $2.55 | $2.71 | +0.22% |
| Jun 2 | $2.37 | $2.55 | $2.74 | +0.27% |
| Jun 3 | $2.36 | $2.55 | $2.76 | +0.33% |
| Jun 4 | $2.34 | $2.55 | $2.77 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.34 | $2.55 | $2.77 | +0.38% |
| Week 2 | $2.27 | $2.56 | $2.88 | +0.77% |
| Week 3 | $2.22 | $2.57 | $2.97 | +1.15% |
| Week 4 | $2.18 | $2.58 | $3.05 | +1.54% |
| Week 5 | $2.14 | $2.59 | $3.13 | +1.93% |
| Week 6 | $2.11 | $2.60 | $3.20 | +2.32% |
| Week 7 | $2.09 | $2.61 | $3.26 | +2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ovid Therapeutics Inc. is a biopharmaceutical company that develops small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Therapeutics Inc. (OVID) is a healthcare stock trading in the public market. The current price is $2.47, the market cap is $461M, and the rank is 3092.
The long-term price outlook is bullish according to the forecast, with the average price projected to rise from $2.47 in 2026 to higher levels in the coming years and ultimately to $42.98 by 2050 in the analyzed horizon. In this forecast, the 2030 average price is $5.33, and the 2050 average price is $42.98.
The forecast also shows upside in cumulative returns, with ROI percentages reaching 116% by 2030 and expanding to 1640.1% by 2050.
A major floor 44.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 15.4% above — a clean break opens room to run.
A major ceiling 24.4% above — clearing it would confirm fresh momentum.
Key OVID support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OVID market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.46 | Buy | $2.49 | Buy |
| MA 10 | $2.53 | Buy | $2.53 | Buy |
| MA 20 | $2.67 | Sell | $2.59 | Sell |
| MA 50 | $2.59 | Sell | $2.50 | Buy |
| MA 100 | $2.13 | Buy | $2.23 | Buy |
| MA 200 | $1.77 | Buy | $1.86 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.95 | Neutral |
| Stoch RSI (14) | 42.58 | Neutral |
| CCI (20) | -52.49 | Neutral |
| Williams %R (14) | -68.75 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -9.29 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 31.25 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 39.11 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 2.46 | Buy |
| ADX (14) | 17.19 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bullish. RSI14 is 40, while the SMA50 is $2.57 and the SMA200 is $1.75.
Support is at $2.39 and resistance at $2.96, framing a recent trading range within the $1.99 to $3.07 band over the last 30 days. The 30-day range shows a low of $1.99 and a high of $3.07, and annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.42 | $2.54 | $3.63 | 0% | Neutral | |
| $2.86 | $3.67 | $5.01 | +44% | Bullish | |
| $3.26 | $4.31 | $6.14 | +70% | Bullish | |
| $3.40 | $4.62 | $6.79 | +82% | Bullish | |
| $3.88 | $5.41 | $8.17 | +113% | Bullish | |
| $4.55 | $6.49 | $10.02 | +155% | Bullish | |
| $5.78 | $8.42 | $13.29 | +231% | Bullish | |
| $6.87 | $10.20 | $16.41 | +301% | Bullish | |
| $7.54 | $11.40 | $18.68 | +349% | Bullish | |
| $8.44 | $13.00 | $21.65 | +412% | Bullish | |
| $14.39 | $24.08 | $42.91 | +848% | Bullish | |
| $22.63 | $43.81 | $86.23 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.42 | $2.54 | $2.99 | +0.00% |
| June 2026 | $2.17 | $2.56 | $3.10 | +0.75% |
| July 2026 | $2.24 | $2.67 | $3.28 | +4.32% |
| August 2026 | $2.25 | $2.70 | $3.35 | +1.05% |
| September 2026 | $2.18 | $2.63 | $3.30 | -2.49% |
| October 2026 | $2.20 | $2.67 | $3.39 | +1.68% |
| November 2026 | $2.29 | $2.80 | $3.57 | +4.59% |
| December 2026 | $2.30 | $2.82 | $3.63 | +0.93% |
Click any year to see its month-by-month OVID forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OVID is projected to trade between $1.42 and $3.63, averaging $2.54 — a potential gain of 0% from today's $2.54. A consolidation phase looks the most probable path here.
Ovid Therapeutics Inc.'s 2027 outlook centres on $3.67, within a $2.86 to $5.01 range. That is up +44% on the projected 2026 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2028, OVID could reach as high as $6.14, with a base case around $4.31 and support toward $3.26 — roughly +70% from $2.54. Buyers look set to stay in control over this stretch.
Expect OVID to range from $3.40 to $6.79 through 2029. The $4.62 average target implies a +82% move from current prices. That is up +7% on the projected 2028 average. Momentum favours further upside here.
The OVID price prediction for 2030 points to an average of $5.41 (low $3.88, high $8.17) — a potential gain of +113% on today's $2.54. Buyers look set to stay in control over this stretch.
In 2031, OVID is projected to trade between $4.55 and $10.02, averaging $6.49 — a potential gain of +155% from today's $2.54. That is up +20% on the projected 2030 average. Momentum favours further upside here.
Ovid Therapeutics Inc.'s 2032 outlook centres on $8.42, within a $5.78 to $13.29 range. That is up +30% on the projected 2031 average. That marks a +231% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, OVID could reach as high as $16.41, with a base case around $10.20 and support toward $6.87 — roughly +301% from $2.54. Momentum favours further upside here.
Expect OVID to range from $7.54 to $18.68 through 2034. The $11.40 average target implies a +349% move from current prices. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The OVID price prediction for 2035 points to an average of $13.00 (low $8.44, high $21.65) — a potential gain of +412% on today's $2.54. Momentum favours further upside here.
In 2040, OVID is projected to trade between $14.39 and $42.91, averaging $24.08 — a potential gain of +848% from today's $2.54. That is up +85% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ovid Therapeutics Inc.'s 2050 outlook centres on $43.81, within a $22.63 to $86.23 range. That is up +82% on the projected 2040 average. That marks a +16.2x change versus current levels. Momentum favours further upside here.
Investing $1,000 in OVID today (≈ 393.700787 OVID) could be worth
$17,248.79
+$16,248.79 (+1625%) by 2050 · US Dollar
Based on the average projected OVID price of $43.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OVIDwould be worth at today's price.
$1,000 invested in OVID on May 27, 2025 (≈ 3,436.426015 OVID) would be worth
$8,728.52
+$7,728.52 (+772.9%) today · 8.73× · US Dollar
Based on a OVID entry price of $0.291 vs. today's $2.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.39 | $1,062.76 | +6.3% |
| 1 month ago | $2.69 | $944.24 | -5.6% |
| 3 months ago | $1.65 | $1,539.39 | +53.9% |
| 6 months ago | $1.78 | $1,426.97 | +42.7% |
| 1 year ago | $0.291 | $8,728.52 | +772.9% |
| All time (5.0y) ago | $4.28 | $593.46 | -40.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OVID forecast.
Our base-case forecast reaches $5.10 around 2030.
Implied market cap at $5.10: $951.86M
The multi-year forecast shows bullish sentiment with rising averages across the late 2020s. The 2027 average is $3.62, the 2028 average is $4.25, and the 2029 average is $4.49, with corresponding ROIs of 46.5%, 72.1%, and 81.7%.
By 2030 the average is $5.33 with ROI 116%. The forecast then projects continued gains through 2031-2035, with 2031 average $6.37 (ROI 157.9%), 2032 average $8.17 (ROI 230.6%), 2033 average $10.08 (ROI 308.1%), 2034 average $11.30 (ROI 357.3%), and 2035 average $12.77 (ROI 417%).
The forecast extends to 2040 and 2050, with 2040 average $23.77 (ROI 862.5%) and 2050 average $42.98 (ROI 1640.1%). The sentiment remains BULLISH, and these figures are estimates, not guarantees.
Tap a question to reveal the answer.
Avg $5.33; min $3.80; max $8.12; ROI 116%; sentiment BULLISH.
Forecast shows rising averages through 2027-2050 with ROI reaching 1640.1% by 2050 and sentiment BULLISH; however 2026 is NEUTRAL.
2033 avg $10.08; min $6.72; max $16.39; ROI 308.1%; sentiment BULLISH.
Current price $2.47; Market cap $461M; Rank 3092.
2040 avg $23.77; ROI 862.5%; 2050 avg $42.98; ROI 1640.1%; sentiment BULLISH.
Ovid Therapeutics Inc. Community Discussion
0Share your Ovid Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.